Table 2.
Baseline Demographic, and Ocular Characteristics for Treatment-Naive Patients With nAMD
| Characteristics | Treatment-Naive Patients With nAMD, N = 6,241* |
| Patient demographics | |
| Mean (SD) age, years | 75.0 (10.17) |
| Gender, n (%) | |
| Male | 2,813 (45.1) |
| Female | 3,428 (54.9) |
| Race, n (%) | |
| Caucasian | 4,152 (66.5) |
| Asian | 1,827 (29.3) |
| Native American | 11 (0.2) |
| Pacific Islander | 5 (0.1) |
| Black | 8 (0.1) |
| Other | 193 (3.1) |
| Baseline lesion characteristics | |
| Lesion type, % | |
| Predominantly classic | 2,723 (43.6) |
| All others | 3,455 (55.4) |
| Lesion size, % | |
| ≤1 DA | 2,362 (37.9) |
| >1 DA | 3,761 (60.3) |
| PED, % | 2,665 (42.7) |
| PCV, % | 572 (9.2) |
| RAP, % | 246 (3.9) |
| Ocular characteristics | |
| VA | |
| n† | 5,797 |
| Mean (SD) VA, ETDRS letters | 49.7 (21.92) |
| Snellen VA | 20/102 |
| CRT | |
| n† | 4,599 |
| Mean (SD) CRT, µm | 365.7 (142.50) |
| IOP | |
| n† | 4,539 |
| Mean (SD), mmHg | 15.4 (3.6) |
| Median time from diagnosis to first treatment, days | 12.0 |
Safety set.
For treatment-naive eyes, the date of first on-study injection with ranibizumab was considered the baseline date.
Data collected until the last recorded follow-up date was used to perform the analyses (i.e., data for 5-year duration of the study).
For 3,379 patients with baseline and 1 year data, the mean (SD) VA at baseline was 51.9 (21.0) letters.
Number of patients at enrollment.
Number of evaluable baseline patients.
CRT, central retinal thickness; DA, disc area; ETDRS, Early Treatment Diabetic Retinopathy Study; PCV, polypoidal choroidal vasculopathy; PED, pigment epithelial detachment; RAP, retinal angiomatous proliferation; SD, standard deviation; VA, visual acuity.